Repligen

Repligen Corporation is a life sciences company focused on the development, production, and commercialization of products used in the process of manufacturing biological drugs. The Company's  bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. Repligen is a manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. The Company also supplies several growth factor products used to increase cell culture productivity in biomanufacturing and has developed and marketed a series of OPUS (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. 

Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
236 (est)
Repligen was founded in 1981 and is headquartered in Waltham, US

Repligen Office Locations

Repligen has offices in Waltham and Lund
Waltham, US (HQ)
100 41 Seyon St
Lund, SE
47 Sankt Lars väg

Repligen Financials and Metrics

Repligen Financials

Repligen's revenue was reported to be $104.5 m in FY, 2016
USD

Revenue (Q3, 2017)

36.6 m

Net income (Q3, 2017)

4.7 m

EBIT (Q3, 2017)

(406 k)

Market capitalization (13-Nov-2017)

1.4 b

Cash (30-Sep-2017)

159.7 m
Repligen's current market capitalization is $1.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.2 m63.5 m83.5 m104.5 m

Revenue growth, %

(7%)31%25%

R&D expense

7.4 m

General and administrative expense

30.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

18.8 m16.3 m15.6 m15.3 m20.8 m21.5 m19.8 m30.6 m32.5 m36.6 m

R&D expense

1.4 m1.2 m1.4 m1.6 m1.6 m1.3 m1.5 m1.5 m1.9 m1.9 m1.7 m1.9 m

General and administrative expense

2.9 m3.4 m4.3 m4.5 m6 m6.2 m6 m7 m8.1 m7.1 m9.2 m11.2 m

Operating expense total

10.8 m11 m12.4 m13.1 m16.8 m16.8 m16.1 m21.6 m23.3 m20.9 m24.9 m27 m37 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.8 m35.4 m54.1 m122.2 m

Accounts Receivable

5.3 m

Inventories

1.2 m2.1 m2.1 m24.7 m

Current Assets

86.4 m80.9 m103.3 m184.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

42.2 m49.2 m33.8 m35.9 m31.2 m40 m48.1 m53.2 m172.6 m157.7 m129.7 m142.2 m159.7 m

Accounts Receivable

394.4 k523.4 k57 k331 k564 k226 k669 k534 k598 k

Inventories

10.1 m11.4 m12.8 m13.3 m12.2 m14.3 m15.9 m21.3 m23.2 m24.5 m24 m26.1 m38.7 m

Current Assets

87.4 m88.7 m73.9 m75.7 m83.5 m93.3 m96.3 m105.2 m217.9 m219.8 m185.8 m195.9 m231.2 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (1.6 m)8.2 m9.3 m11.7 m

    Depreciation and Amortization

    1.3 m4 m4.6 m5.3 m

    Accounts Receivable

    3.6 m(1.6 m)(3.7 m)(3.2 m)

    Inventories

    (870.3 k)(860.1 k)(6.1 m)(6.2 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    5.9 m4.3 m2.8 m1.5 m2.9 m3.6 m2.5 m1.6 m5.5 m6.7 m3.1 m4.7 m

    Depreciation and Amortization

    1.2 m2.5 m3.8 m

    Accounts Receivable

    394.4 k523.4 k57 k(1.1 m)892 k(3.3 m)669 k598 k

    Inventories

    12.8 m13.3 m12.2 m14.3 m15.9 m(3.1 m)(5.1 m)(6.5 m)24 m38.7 m
      Y, 2017

      Financial Leverage

      1.3 x
      Show all financial metrics

      Repligen Market Value History

      Repligen's Web-traffic and Trends

      Repligen Online and Social Media Presence

      Repligen Company Life and Culture

      You may also be interested in